The Impact of METTL3 on MDM2 Promotes Podocytes Injury During Diabetic Kidney Disease
Journal of Cellular and Molecular Medicine · 2025
DOI: 10.1111/jcmm.70627 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, 2025. Verfasst von Han Wu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine, The Second Affiliated Hospital of Guangdong Medical University, Zhanjiang, China. Hauptthemen laut MEDLINE: Podocytes, Diabetic Nephropathies, Methyltransferases, Proto-Oncogene Proteins c-mdm2. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Guangdong Medical University Clinical and Basic Science Innovation Special Project, The National Natural Science Foundation of China, China Postdoctoral Science Foundation.
Abstract (Originalsprache)
N6‐Methyladenosine (m6A) methylation plays a role in various pathological processes, including renal fibrosis and aging. Our previous studies have highlighted abnormal expression of the methyltransferase enzyme, methyltransferase like 3 (METTL3), in aging kidney tissues. This study aims to elucidate the regulatory mechanisms of METTL3 in diabetic kidney disease (DKD) by establishing a conditional METTL3 knockout model. We observed elevated m6A levels in the kidneys of type I diabetic mice and in cultured mouse podocytes exposed to advanced glycation end products (AGEs). These increases were attributed to enhanced METTL3 expression. Significantly, podocyte‐specific METTL3 knockdown mitigated injury in streptozotocin (STZ)‐induced diabetic mice, evidenced by reduced urine albuminuria and renal pathology. We discovered that METTL3 induced abnormal m6A modification of murine double minute 2 (MDM2), which triggered its degradation in an IGF2BP2 (insulin‐like growth factor 2 mRNA‐binding protein 2)‐dependent manner. This modification led to increased MDM2 expression, activating the Notch signalling pathway and inducing podocyte cell cycle arrest under diabetic conditions, which further released inflammatory factors and caused podocyte dedifferentiation. Our findings suggest that targeting m6A modification via METTL3 could be an effective strategy for treating DKD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Laboratory Medicine, The Second Affiliated Hospital of Guangdong Medical University, Zhanjiang, China.
- School of Medicine Xiamen University, Xiamen, China.
- Respiratory Medicine, The Second Affiliated Hospital of Guangdong Medical University, Zhanjiang, China.
- Clinical Research and Experimental Center, Affiliated Hospital of Guangdong Medical University, Zhanjiang, China.
- Department of Nephrology, The First Hospital of China Medical University, Shenyang, China.
- Department of Urology, The First Hospital of China Medical University, Shenyang, China.
ORCID-Profile: Qingjun Pan, Hongyuan Yu, Li Xu
Förderung
- Guangdong Medical University Clinical and Basic Science Innovation Special Project
- The National Natural Science Foundation of China
- China Postdoctoral Science Foundation
- Guangdong Natural Science Foundation-General Program
- Zhanjiang Science and Technology Development Special Project
- Postdoctoral Research Foundation of China
Zitieren
APA
Wu, H., Yu, Z., Yang, Y., Han, Z., Pan, Q., Chen, Y., Yu, H., Shen, S., & Xu, L. (2025). The Impact of METTL3 on MDM2 Promotes Podocytes Injury During Diabetic Kidney Disease. Journal of Cellular and Molecular Medicine. https://doi.org/10.1111/jcmm.70627
Vancouver
Wu H, Yu Z, Yang Y, Han Z, Pan Q, Chen Y, et al. The Impact of METTL3 on MDM2 Promotes Podocytes Injury During Diabetic Kidney Disease. Journal of Cellular and Molecular Medicine. 2025. doi:10.1111/jcmm.70627
BibTeX
@article{Wu2025,
author = {Wu, Han and Yu, Ziyang and Yang, Yitian and Han, Zhuoting and Pan, Qingjun and Chen, Ying and Yu, Hongyuan and Shen, Siman and Xu, Li},
title = {The Impact of METTL3 on MDM2 Promotes Podocytes Injury During Diabetic Kidney Disease},
journal = {Journal of Cellular and Molecular Medicine},
year = {2025},
doi = {10.1111/jcmm.70627}
}
EUVIMED